Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: April 17, 2024

Abstract Background The antiviral drug Nirmatrelvir was found to be a key in controlling the progression of pneumonia during infectious phase COVID-19. However, there are very few options for effective treatment cancer patients who have viral pneumonia. Glucocorticoids is one means control pneumonia, but many adverse events. EGCG natural low toxic compound with anti-inflammatory function. Thus, this study designed investigate safety and efficacy epigallocatechin-3-gallate (EGCG) aerosol COVID-19 populations. Methods as prospective, single-arm, open-label I/II trial at Shandong Cancer Hospital Institute, between January 5, 2023 March 31,2023 on radiographic signs after confirmed novel coronavirus infection. These were treated nebulization 10 ml three times daily least seven days. concentrations increased from 1760-8817umol/L 4 levels dose escalation following standard Phase I design 3–6 per level. Any grade event caused by considered dose-limiting toxicity (DLT). maximum tolerated (MTD) defined highest less than one-third experiencing limiting (DLT) due EGCG. primary end points CT findings, former graded Common Terminology Criteria Adverse Events (CTCAE) v. 5.0. secondary point laboratory parameters before treatment. Result A total 60 high risk factors severe (factors such old age, smoking combined complications)were included I-II study. 54 final analysis pathologically tumor burden completed whole course patient bucking level 1760 umol/L no acute associated has been reported second or third gradients. At 8817umol/L, Grade 1 events nausea stomach discomfort occurred two patients, which resolved spontaneously within hour. After week treatment, showed that incidence non-progression 82% (32/39), improvement rate 56.4% (22/39). There significant difference inflammation-related (white blood cell count, lymphocyte IL-6, ferritin, C-reactive protein lactate dehydrogenase) Conclusion Aerosol inhalation well tolerated, preliminary investigation population suggests may COVID-19-induced can promote moderate prevent them developing into Trial registration ClinicalTrials.gov Identifier: NCT05758571. Date registration: 8 February 2023.

Language: Английский

---

A comprehensive overview of dry powder inhalers for pulmonary drug delivery: Challenges, advances, optimization techniques, and applications

Journal of Drug Delivery Science and Technology, Journal Year: 2023, Volume and Issue: 84, P. 104553 - 104553

Published: May 8, 2023

Language: Английский

---

Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 355, P. 292 - 311

Published: Feb. 9, 2023

Language: Английский

---

Inhalable nanomedicine for lung cancer treatment

Smart Materials in Medicine, Journal Year: 2024, Volume and Issue: 5(2), P. 261 - 280

Published: April 11, 2024

Lung cancer has surpassed other types of to become the primary cause cancer-related deaths. Surgery stands as foremost clinical treatment strategy available for tackling this condition, but it receives a low efficiency most patients. In recent years, some adjuvant therapies are employed improve lung efficiency, such chemotherapy, targeted therapy and immunotherapy. However, these strategies have not significantly increased overall survival Additionally, random distribution drugs will induce severe side effects. Nanomedicines got great attentions boost drug effect reduce adverse reactions, including liposome-based nanoparticles, polymeric inorganic exosomes. Importantly, nanomedicines contribute improving bioavailability, stability residency in target regions. Benefiting from physiological characteristics lung, inhaled pulmonary delivery combination with nanomedicine provide non-invasive effective treating cancer. Furthermore, use targeting ligands enables precise loaded cells. Inhaled exhibits unique sustained release behaviors alveoli, amplifying therapeutic reducing This review aims discuss various methods delivering treat also summarizes clearance mechanism lung. Overall, focuses on application different inhalable nanomedicines, which may inspire development more treatments against

Language: Английский

---

Ranking the risks of eighty pharmaceuticals in surface water of a megacity: A multilevel optimization strategy

The Science of The Total Environment, Journal Year: 2023, Volume and Issue: 878, P. 163184 - 163184

Published: March 30, 2023

Language: Английский

---

An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models

Science Translational Medicine, Journal Year: 2023, Volume and Issue: 15(711)

Published: Aug. 30, 2023

The Omicron variant continuously evolves under the humoral immune pressure exerted by vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, resulting subvariants display further evasion antibody escape. An engineered angiotensin-converting enzyme (ACE2) decoy composed of high-affinity ACE2 an IgG1 Fc domain could offer alternative modality to neutralize SARS-CoV-2. We previously reported its broad spectrum therapeutic potential in rodent models. Here, we demonstrate that retains neutralization activity against subvariants, including currently emerging XBB BQ.1 strains, which completely evade antibodies clinical use. SARS-CoV-2, suboptimal concentration neutralizing drugs, generated SARS-CoV-2 mutants escaping wild-type monoclonal antibodies, whereas no escape mutant emerged decoy. Furthermore, inhalation aerosolized decoys improved outcomes rodents infected with at a 20-fold lower dose than intravenous administration. Last, exhibited efficacy for cynomolgus macaques These results indicate this represents promising strategy overcome immune-evading variants liquid aerosol be considered as noninvasive approach enhance COVID-19 treatments.

Language: Английский

---

Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration

mBio, Journal Year: 2023, Volume and Issue: 14(5)

Published: Sept. 28, 2023

Many of the current pandemic threats are caused by viruses that infect respiratory tract. Remarkably though, majority vaccines and antiviral drugs administered via alternative routes. In this perspective, we argue pulmonary route administration deserves more attention in search for novel therapeutic strategies against virus infections. Firstly, at viral portal entry can induce a broader immune response, employing mucosal arm system; secondly, direct target site leads to superior bioavailability, enabling lower dosing reducing chance side effects. We further elaborate on why may effect compared intranasal provide reasons dry powder formulations inhalation have significant advantages over standard liquid formulations.

Language: Английский

---

Novel inhalable nano-based/microparticles for enhanced sustained pulmonary delivery of remdesivir - a patient malleable treatment for coronaviruses infection: in vitro aerosolization, cytotoxicity assays and antiviral activity studies.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: unknown, P. 106196 - 106196

Published: Sept. 1, 2024

Language: Английский

---

Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract

Trends in Food Science & Technology, Journal Year: 2022, Volume and Issue: 132, P. 40 - 53

Published: Dec. 28, 2022

Language: Английский

---

Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities

Pulmonary Pharmacology & Therapeutics, Journal Year: 2022, Volume and Issue: 77, P. 102170 - 102170

Published: Oct. 12, 2022

Language: Английский

---